Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q2 FY21 results · Jul–Sep 2020
Suven Life Sciences reported revenue from operations of ₹8.98 crore (down 96.7% from Q2 FY20) and net loss of ₹15.66 crore for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8.98 | 274.31 | −96.7% | 1.43 | +528.6% |
| Other income | 2.28 | 5.59 | −59.2% | 2.53 | −10.0% |
| Total income | 11.26 | 279.90 | −96.0% | 3.96 | +184.4% |
| Profit before tax | (16.65) | 99.66 | Turned loss | (12.96) | Loss widened |
| Net profit for the period | (15.66) | 63.31 | Turned loss | (10.49) | Loss widened |
| EPS, basic (₹) | (1.23) | 4.97 | Turned loss | (0.82) | Loss widened |
| Net margin (%) | -174.4 | 23.1 | -734.2 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8.98 | 274.31 | −96.7% | 1.43 | +528.6% |
| Other income | 2.28 | 5.59 | −59.2% | 2.53 | −10.0% |
| Total income | 11.26 | 279.90 | −96.0% | 3.96 | +184.4% |
| Profit before tax | (2.89) | 108.67 | Turned loss | (6.54) | Loss narrowed |
| Net profit for the period | (1.90) | 72.32 | Turned loss | (4.08) | Loss narrowed |
| EPS, basic (₹) | (0.15) | 5.68 | Turned loss | (0.32) | Loss narrowed |
| Net margin (%) | -21.2 | 26.4 | -285.4 |
Consolidated
- Filed with BSE
- 29 Oct 2020, 15:49 IST
- Board meeting
- 27 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2020, 15:49 IST
- Board meeting
- 27 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE